Teva Pharmaceutical Industries Ltd: PharmaVitae Profile

Teva Pharmaceutical Industries Ltd: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Teva in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Teva's performance against key rivals in the prescription pharmaceutical sector

*Assess how continued M&A activity has allowed Teva to remain the leading global generics player, despite increased competition from Sandoz

*Analyze how the company is set to experience further uplift from M&A, with the acquisition of Barr due to be completed by early 2009.

CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Teva: PharmaVitae forecasts at a glance 6
Strategic insight 7
Untapped markets offer potential for growth 7
Accelerated growth through M&A 8
Teva is set to extend its lead due to scale advantages 9
SWOT analysis 10
CHAPTER 3 QUARTERLY NEWS UPDATE 14
Deals and alliances 14
Product deals 14
CHAPTER 4 COMPANY INTRODUCTION 15
Key findings 15
Background 16
Key corporate developments 16
M&A history 16
Sicor Acquisition 18
IVAX Acquisition 18
M&A strategy 19
CHAPTER 5 COMPANY SALES 20
Prescription pharmaceutical sales and growth rate analysis, 2001-13 20
Product analysis 22
Product analysis, 2001-07 22
Product analysis, 2007-13 25
Therapy area analysis 30
Therapy area analysis, 2001-07 31
Therapy area analysis, 2007-13 34
Therapy area focus, 2001-13 37
Geographic analysis 38
Geographic analysis, 2001-07 39
Geographic analysis, 2007-13 40
Geographic focus, 2001-13 42
Launch/core/expiry analysis 43
Explanation of launch/core/expiry analysis 43
Launch analysis, 2007-13 44
Launch/core/expiry configuration, 2007-13 46
Molecule type analysis 47
Molecule type analysis, 2001-07 48
Molecule type analysis, 2007-13 49
Externalization analysis 52
Externalization analysis, 2001-07 52
CHAPTER 6 KEY PRODUCTS AND COMPETITORS 54
Key findings 54
References 55
Abbreviations 55
Exchange rates 56
List of Tables
Table 1: Teva - PharmaVitae forecasts at a glance 6
Table 2: Teva product deals and alliances, Q1-Q3 2008 14
Table 3: Teva product portfolio overview ($m), 2001-07 22
Table 4: Teva product portfolio overview ($m), 2007-13 25
Table 5: Teva product portfolio overview ($m), 2001-07 31
Table 6: Teva product portfolio overview ($m), 2007-13 34
Table 7: Teva portfolio overview by geographic region ($m), 2001-07 39
Table 8: Teva portfolio overview by geographic region ($m), 2007-13 40
Table 9: Teva launch portfolio overview ($m), 2007-13 44
Table 10: Teva portfolio overview by molecule type ($m), 2001-07 48
Table 11: Teva product portfolio overview by molecule type ($m), 2007-13 49
Table 12: Teva product portfolio overview by source ($m), 2001-07 52
Table 13: Exchange rates, 2007 56
List of Figures
Figure 1: Teva prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5
Figure 2: Generics penetration by volume in different markets 7
Figure 3: Teva's growth has accelerated through M&A 8
Figure 4: Teva's leading position will 9
Figure 5: SWOT analysis of Teva 10
Figure 6: Teva's M&A/divestment history, 2001-07 18
Figure 7: Teva prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 20
Figure 8: Teva key sales growth driver & resistors ($m), 2001-07 24
Figure 9: Teva key sales growth drivers & resistors ($m), 2007-13 28
Figure 10: Teva prescription pharmaceutical sales by therapy area ($m), 2001-13 30
Figure 11: Teva prescription pharma sales by therapy area (% of total), 2001-13 37
Figure 12: Teva prescription pharmaceutical sales by geographic region ($m), 2001-13 38
Figure 13: Teva growth drivers and resistors by geographic region ($m), 2001-07 39
Figure 14: Teva drivers and resistors by geographic region ($m), 2007-13 41
Figure 15: Teva prescription pharmaceutical sales by geographic region (% of total), 2001-13 42
Figure 16: Teva launch/core/expiry configuration ($m), 2007-13 46
Figure 17: Teva prescription pharmaceutical sales by molecule type ($m), 2001-13 47
Figure 18: Teva growth drivers and resistors by molecule type ($m), 2007-13 51
Figure 19: Teva prescription pharmaceutical sales by source ($m), 2001-13 52
Figure 20: Teva growth drivers and resistors by source ($m), 2001-07 53